Becton, Dickinson and Company
BDX

$64.28 B
Marketcap
$222.39
Share price
Country
$-0.25
Change (1 day)
$249.89
Year High
$218.75
Year Low

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

marketcap

P/E ratio for Becton, Dickinson and Company (BDX)

P/E ratio as of 2024: 40.48

According to Becton, Dickinson and Company's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 40.48. At the end of 2023 the company had a P/E ratio of 49.87.

P/E ratio history for Becton, Dickinson and Company from 1985 to 2024

PE ratio at the end of each year

Year P/E ratio
2024 40.48
2023 49.87
2022 35.70
2021 33.14
2020 72.41
2019 54.57
2018 214.12
2017 38.02
2016 38.19
2015 37.69
2014 18.10
2013 14.72
2012 13.52
2011 12.44
2010 12.85
2009 13.28
2008 16.96
2007 22.23
2006 22.66
2005 17.80
2004 27.12
2003 16.38
2002 14.89
2001 22.93
2000 16.61
1999 24.82
1998 41.63
1997 20.11
1996 20.10
1995 16.83
1994 15.24
1993 40.11
1992 13.92
1991 13.40
1990 13.71
1989 12.93
1988 13.69
1987 17.88
1986 18.18
1985 12.48